Petr Husa

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16

Strategies to manage hepatitis<scp>C</scp>virus (<scp>HCV</scp>) disease burden

Heiner Wedemeyer, A.‐S. Duberg, Marı́a Buti et al. · Journal of Viral Hepatitis · 2014 · 181 citations · Full text

Pharmacy, Infectious Disease Control, Infectious Diseases +13

Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B

Scott Fung, Peter Kwan, Milotka Fabri et al. · Gastroenterology · 2013 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders

Eugene R. Schiff, Jules L. Dienstag, Selim Karayalçın et al. · Journal of Hepatology · 2003 · 117 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial

Francisco M. Marty, Joan Vidal-Puigserver, Carol L. Clark et al. · The Lancet Respiratory Medicine · 2017 · 104 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +5